Results 301 to 310 of about 157,438 (357)

Cough and ACE Inhibitors [PDF]

Survey of Anesthesiology, 1992
To assess the prevalence of cough as a side effect of angiotensin-converting enzyme inhibitor antihypertensive therapy, we reviewed 300 consecutive patient charts from a private practice and 200 consecutive patient charts from a university-based referral center for hypertension.
Marvin Moser, Steven R. Simon, Wendy E. Berland, Henry R. Black   +3 more
openaire   +3 more sources

ACE Inhibitors in the Elderly [PDF]

Angiology, 1991
As the population with hypertension becomes older, it is important to determine the properties of angiotensin-converting enzyme (ACE) inhibitors in the elderly. The pharmacokinetics and efficacy of captopril, enalapril, and a new once-daily ACE inhibitor, quinapril for the treatment of hypertension in young and elderly patients are reviewed, and the ...
Allen J. Sedman, Edward L. Posvar
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Ace Inhibitors and Cough

Angiology, 1994
Probably the most common and irritating side effect of angiotensin-converting enzyme (ACE) inhibitors is cough. In this retrospective study the incidence of cough was investigated in 1113 patients with arterial hypertension who were receiving ACE inhibitors alone or in combination with other antihypertensive agents.
POSTACI, N, YESIL, M, YESIL, S, BAYATA, S   +3 more
openaire   +4 more sources

ACE-inhibitors and atherosclerosis

European Journal of Epidemiology, 1992
The involvement of the circulating and local renin-angiotensin system in atherosclerotic process has been hypothesized on the basis of experimental data showing presence and specific actions of the components of this system in the vascular wall. In particular, angiotensin II may participate in well known events in atherogenesis as the control of smooth
Claudio Borghi, D Degli Esposti, Ettore Ambrosioni, Stefano Bacchelli   +3 more
openaire   +3 more sources

ACE inhibitors and proteinuria

Pharmacy World and Science, 1996
This review discusses the clinical consequences of urinary protein loss and the effects of inhibitors of the angiotensin converting enzyme (ACE) on this clinical finding. Proteinuria appears to be an important risk factor for renal function deterioration and for cardiovascular mortality.
Ron T. Gansevoort, de Dick Zeeuw, de Paul Jong   +2 more
openaire   +3 more sources

Nitrendipine and ACE Inhibitors

Journal of Cardiovascular Pharmacology, 1988
There is evidence from several studies of the clinical usefulness of an antihypertensive regimen combining a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor. The mechanisms of this mutual potentiation between agents of these two classes are probably numerous.
openaire   +3 more sources

Formulary Management of ACE Inhibitors

PharmacoEconomics, 1996
An increasing number of ACE inhibitors have become available in recent years. Because these agents are all similar, careful scrutiny is required in order to determine specific advantages of particular agents when making formulary decisions. Differences between agents with regard to structure and tissue specificity have been identified, but the clinical
Yedinak Kc, Gerbrandt Kr
openaire   +3 more sources

Ace Inhibitors in Heart Failure

Scandinavian Journal of Urology and Nephrology, 1984
(1984). Ace Inhibitors in Heart Failure. Scandinavian Journal of Urology and Nephrology: Vol. 18, Scandinavian Symposium on the Physiology and Clinical Use of Ace Inhibitors, pp. 115-120.
openaire   +4 more sources

ACE INHIBITORS

The Lancet, 1988
J E, Scoble, P, Sweny, J F, Moorhead
openaire   +4 more sources

ACE Inhibitors and ARB’s

2014
Pharmacologic manipulation of afterload or systemic vascular resistance (SVR) has become increasingly important in the management of pediatric cardiac patients, just as it has for adult cardiac patients.
Carol G. Vetterly, Carol G. Vetterly, Ryan Flanagan, Ryan Flanagan, Ricardo Munoz   +4 more
openaire   +2 more sources